No abstract

No abstract

The frequency and clinical significance of the hyperkalemia associated with spironolactone therapy was studied by analyzing 755 serum potassium values obtained on 29 patients with cirrhosis and ascites. The patients were classified as follows:I) control group treated intermittently with combinations of conventional diuretics; and 2) spironolactone groups-(A) patients treated with spironolactone alone, and (B and C) nonazotemic and slightly azotemic patients, respectively, treated with spironolactone plus diuretics.Hyperkalemia was indicated in 3.3 per cent of 302 control serum potassium determinations, and in 48 per cent of 325 determinations made during spironolactone treatment. The increase in serum potassium concentration was more marked in the slightly azotemic group, although the initial levels were no higher than in the other groups of patients. Hyperkalemic intermittent paralysis associated with spironolactone therapy occurred in 5 patients. Studies of the urinary excretory patterns suggested a distal as well as a proximal tubular site of action of spironolactone. The significance of the tubular levels of spironolactone action in the development of hyperkalemia is discussed.

No abstract

Glibenclamide (G) had a diuretie effect during ad libitum fluid intake as weil as during maximal sustained water diuresis in patients with pituitary diabetes insipidus. The diuretic effect oould be demonstrated also in healthy subjeets during maximal sustained water diuresis. No antagonism was found between small doses of Iysine-vasopressin and G. Diuretie action of G seems not to be media ted through inhibition of the release or/and renal effect of antidiuretic hormone (ADH). An effect on the water reabsorbing mechanism not depending on ADH was supposed. Diuretic effect of G has important clinical implications.